> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Boston Scientific Names Joe Fitzgerald COO And Splits Reporting Into Three Segments In 2027
- URL: https://www.bullished.co/boston-scientific-names-joe-fitzgerald-coo-and-splits-reporting-into-three-segments-in-9c0a20b8/
- Published: 2026-10-07T10:21:07.000Z
- Updated: 2026-10-07T10:21:07.000Z
- Description: Fitzgerald, 63, gets a $1,050,000 base salary and a $7,000,000 equity award as COO starting January 1, 2027, the 8-K says.
- Author: Matteo Parrino
- Tags: SEC Filings, BSX, Industry: Healthcare

Boston Scientific promoted cardiovascular group president Joe Fitzgerald to [chief operating officer](https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000064/bsx-20261001.htm?ref=bullished.co), effective January 1, 2027, according to an 8-K filed Wednesday. The company will also begin reporting three segments the same day: Interventional Therapies, Rhythm Solutions and MedSurg.

## What the 8-K says

Fitzgerald is now executive vice president and group president, Cardiovascular. As executive vice president and COO, he will oversee the company's global operations, business units and regions, according to the [press release](https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000064/ex991-octoberbscpressrelea.htm?ref=bullished.co) attached to the filing.

The company said the three-segment structure is meant to enable faster decision making and support strategic allocation of investments across the portfolio.

Three leaders will run the segments, and each will report to Fitzgerald:

- Lance Bates leads Interventional Therapies, which will include the Penumbra business after the anticipated close of that acquisition.
- Nick Spadea-Anello leads Rhythm Solutions.
- Stephen Morse leads MedSurg and Asia Pacific.

A footnote in the release lists the contents. Interventional Therapies covers Interventional Cardiology, Vascular Therapies and Interventional Oncology & Embolization. Rhythm Solutions covers Electrophysiology, WATCHMAN and Cardiac Rhythm Management & Diagnostics. MedSurg covers Endoscopy, Urology and Neuromodulation.

Chairman and CEO Mike Mahoney said the changes "reflect the scale and breadth of our business today and the opportunities ahead."

## Fitzgerald's pay and path

Under his offer letter, Fitzgerald gets a $1,050,000 base salary and a bonus target of 110% of that salary. His 2027 equity award has a grant-date value of $7,000,000 and is expected in February 2027\. It will come as stock options and restricted stock units, including performance-based units, vesting 25% per year.

He stays eligible for the Executive Retirement Plan, which pays a lump sum of 2.5 months of base salary per year of service, capped at 36 months. He also keeps standard change-in-control protections.

Fitzgerald joined the company in 1990\. He ran Rhythm Management from 2014 to 2020 and Interventional Cardiology from July 2020 to January 2022\. He has held his current group role since May 2022.

## A separate change in accounting

On October 1, the board named Mark Bickel, 49, chief accounting officer effective March 1, 2027\. He is now finance and global controller of the Cardiovascular business, a post he has held since January 2025.

He replaces Emily Woodworth, who becomes senior vice president, global finance controller and finance transformation. The filing says her move is not due to any disagreement over financial statements, internal controls, operations, policies or practices.

The Penumbra close sets when that business joins Interventional Therapies, and Fitzgerald's first grant as COO is expected in February 2027.

### Sources

- [8-K Filing — BOSTON SCIENTIFIC CORP (BSX)](https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000064/bsx-20261001.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex991-octoberbscpressrelea.htm — BOSTON SCIENTIFIC CORP 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000885725/000088572526000064/ex991-octoberbscpressrelea.htm?ref=bullished.co) — SEC EDGAR